GlassScriptPhysician profile
Maged I Hosny
NPI 1326003351
$1,208.14
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $230 · 2021: $60.52 · 2022: $20.87 · 2023: $72.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $72.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $72.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $181.36 | 2019-2023 | Cimzia |
| Amgen INC. | $151.37 | 2019-2020 | |
| Abbvie INC. | $106.43 | 2019-2020 | |
| Janssen Biotech, INC. | $101.25 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $100.21 | 2019 | |
| Pfizer INC. | $87.38 | 2019-2021 | |
| Lilly USA, LLC | $79.15 | 2019-2020 | |
| Organon LLC | $68.74 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $66.54 | 2019 | |
| Horizon Therapeutics Plc | $41.16 | 2019 | |
| Medexus Pharma, INC. | $39.90 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $37.30 | 2019-2020 | |
| Glaxosmithkline, LLC. | $34.67 | 2019 | |
| Mallinckrodt Enterprises LLC | $24.78 | 2019 | |
| Celgene Corporation | $20.95 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $18.79 | 2019 | |
| Scilex Pharmaceuticals INC. | $17.99 | 2019 | |
| Mallinckrodt Hospital Products INC. | $16.60 | 2020 | |
| Pacira Therapeutics, INC. | $13.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maged Hosny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.